{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T08:36:11Z","timestamp":1775032571013,"version":"3.50.1"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":3200,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Women with breast cancer have better cancer-related outcomes with the use of aromatase inhibitors (AIs), but the physiological suppression of estradiol can negatively affect sexual functioning because of unpleasant urogenital and vaginal symptoms. Local health care practitioners have observed that the benefits of vaginal testosterone in allaying these unpleasant symptoms in women with breast cancer are similar to the benefits of vaginal estrogen in women without breast cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>The aim of this study was to evaluate the effects of using a daily vaginal testosterone cream on the reported sexual health quality of life in women with breast cancer taking AI therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Thirteen postmenopausal women with breast cancer on AI therapy and experiencing symptoms of sexual dysfunction were recruited from an oncology practice. The women were prescribed a 300\u2009\u03bcg testosterone vaginal cream daily for 4 weeks. During the first study visit, a vaginal swab was obtained to rule out the presence of Candida species or Gardnerella vaginalis in participants. Women with positive vaginal swabs were treated prior to starting the vaginal testosterone therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measure<\/jats:title>\n                  <jats:p>\u2002The Female Sexual Function Index (FSFI) survey, measuring female sexual health quality of life, was administered during the first study visit and at the final study visit, after completing testosterone therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Twelve patients completed 4 weeks of daily vaginal testosterone therapy. When compared with baseline FSFI scores, there was a statistically significant improvement for individual domain scores of desire (P\u2009=\u20090.000), arousal (P\u2009=\u20090.002), lubrication (P\u2009=\u20090.018), orgasm (P\u2009=\u20090.005), satisfaction (P\u2009=\u20090.001), and pain (P\u2009=\u20090.000). Total domain scores reflecting sexual health quality of life also improved when compared with baseline (P\u2009=\u20090.000).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The use of a compounded testosterone vaginal cream applied daily for 4 weeks improves reported sexual health quality of life in women with breast cancer taking AIs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/sm2.22","type":"journal-article","created":{"date-parts":[[2014,1,15]],"date-time":"2014-01-15T06:19:41Z","timestamp":1389766781000},"page":"8-15","source":"Crossref","is-referenced-by-count":50,"title":["Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: A Pilot Study of the Effects of Vaginal Testosterone Therapy"],"prefix":"10.1093","volume":"2","author":[{"given":"Melissa","family":"Dahir","sequence":"first","affiliation":[{"name":"Omaha OB-GYN Associates , Omaha, NE , USA"},{"name":"Department of Pelvic Pain & Sexual Medicine , Omaha, NE , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dianne","family":"Travers-Gustafson","sequence":"additional","affiliation":[{"name":"Creighton University , Omaha, NE , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,4,1]]},"reference":[{"key":"2023010704070887700_bb0010","article-title":"U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999\u20132009 Incidence and Mortality Web-based Report [Internet]. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute","year":"2012"},{"key":"2023010704070887700_bb0015","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1023\/A:1020299707510","article-title":"Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database","volume":"76","author":"Anderson","year":"2002","journal-title":"Breast Cancer Res Treat"},{"key":"2023010704070887700_bb0020","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/annonc\/mdj127","article-title":"Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors","volume":"17","author":"Kendall","year":"2006","journal-title":"Ann Oncol"},{"key":"2023010704070887700_bb0025","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1470-2045(07)70385-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial","volume":"9","author":"Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group","year":"2008","journal-title":"Lancet Oncol"},{"key":"2023010704070887700_bb0030","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3109\/13697137.2011.620658","article-title":"Menopausal-type symptoms among breast cancer patients on aromatase inhibitor therapy","volume":"15","author":"Gallicchio","year":"2012","journal-title":"Climacteric"},{"key":"2023010704070887700_bb0035","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s00404-011-2181-6","article-title":"Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors","volume":"285","author":"Moegele","year":"2012","journal-title":"Arch Gynecol Obstet"},{"key":"2023010704070887700_bb0040","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1080\/13697130802244422","article-title":"A survey among breast cancer survivors: Treatment of the climacteric after breast cancer","volume":"11","author":"Antoine","year":"2008","journal-title":"Climacteric"},{"key":"2023010704070887700_bb0045","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.ajog.2010.08.035","article-title":"Urogenital disorders in women with adjuvant endocrine therapy after early breast cancer","volume":"204","author":"Baumgart","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"2023010704070887700_bb0050","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1743-6109.2010.02034.x","article-title":"Sexual function after breast cancer","volume":"8","author":"Panjari","year":"2011","journal-title":"J Sex Med"},{"key":"2023010704070887700_bb0055","article-title":"Surveillance Epidemiology and End Results [SEER]. Cancer of the breast: SEER stat fact sheets [Internet]","year":"2012"},{"key":"2023010704070887700_bb0060","article-title":"U.S. Department of Health and Human Services. Testosterone [Internet]","year":"2013"},{"key":"2023010704070887700_bb0065","article-title":"Title 175: Health care facilities and services licensure, Chapter 8: Pharmacies [Internet]","author":"Nebraska Health and Human Services Regulation and Licensure","year":"2007"},{"key":"2023010704070887700_bb0070","first-page":"228","article-title":"Postmenopausal vaginal atrophy and atrophic vaginitis","volume":"314","author":"Pandit","year":"1997","journal-title":"Am J Med Sci"},{"key":"2023010704070887700_bb0075","article-title":"BD Affirm VPIII Microbial Identification Test [Internet]","author":"Becton Dickinson and Company, United States","year":"2012"},{"issue":"3 suppl","key":"2023010704070887700_bb0080","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1743-6109.2005.00131.x","article-title":"Practical aspects in the management of vaginal atrophy and sexual dysfunction in perimenopausal and postmenopausal women","volume":"2","author":"Goldstein","year":"2005","journal-title":"J Sex Med"},{"key":"2023010704070887700_bb0085","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0140-6736(83)90920-0","article-title":"Anaerobic vaginosis (non-specific vaginitis): Clinical, microbiological, and therapeutic findings","volume":"2","author":"Blackwell","year":"1983","journal-title":"Lancet"},{"issue":"110","key":"2023010704070887700_bb0090","article-title":"Diseases characterized by vaginal discharge: 2010 treatment guidelines [Internet]","author":"Workowski","year":"2010"},{"key":"2023010704070887700_bb0095","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/009262300278597","article-title":"The Female Sexual Function Index (FSFI): A multidimensional self-report instrument for the assessment of female sexual function","volume":"26","author":"Rosen","year":"2000","journal-title":"J Sex Marital Ther"},{"key":"2023010704070887700_bb0100","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1002\/cncr.26739","article-title":"Psychometric validation of the Female Sexual Function Index (FSFI) in cancer survivors","volume":"118","author":"Baser","year":"2012","journal-title":"Cancer"},{"key":"2023010704070887700_bb0105","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/713847100","article-title":"Validation of the Female Sexual Function Index (FSFI) in women with female orgasmic disorder and in women with hypoactive sexual desire disorder","volume":"29","author":"Meston","year":"2003","journal-title":"J Sex Marital Ther"},{"key":"2023010704070887700_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00926230590475206","article-title":"The female sexual function index (FSFI): Cross-validation and development of clinical cutoff scores","volume":"31","author":"Wiegel","year":"2005","journal-title":"J Sex Marital Ther"},{"issue":"3 suppl","key":"2023010704070887700_bb0115","first-page":"97","article-title":"Role of testosterone in feminine sexuality","volume":"26","author":"Nappi","year":"2003","journal-title":"J Endocrinol Invest"},{"key":"2023010704070887700_bb0120","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1001\/archpsyc.57.2.149","article-title":"Time course of effects of testosterone administration on sexual arousal in women","volume":"57","author":"Tuiten","year":"2000","journal-title":"Arch Gen Psychiatry"},{"key":"2023010704070887700_bb0125","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1743-6109.2008.01121.x","article-title":"Testosterone therapy in women with gynecological and sexual disorders: A triumph of clinical endocrinology from 1938 to 2008","volume":"6","author":"Traish","year":"2009","journal-title":"J Sex Med"},{"key":"2023010704070887700_bb0130","article-title":"Subcutaneous testosterone-anastrozole therapy in breast cancer survivors","author":"Glaser","journal-title":"In: American Society of Clinical Oncology Breast Cancer Symposium October 2010"},{"key":"2023010704070887700_bb0135","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1634\/theoncologist.2010-0435","article-title":"Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: A phase I\/II study","volume":"16","author":"Witherby","year":"2011","journal-title":"Oncologist"},{"key":"2023010704070887700_bb0140","article-title":"Laboratory test directory: Estradiol [Internet]","author":"ARUP Laboratories, National Reference Laboratory"},{"key":"2023010704070887700_bb0145","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1200\/JCO.2009.23.1274","article-title":"Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen","volume":"28","author":"Dowsett","year":"2010","journal-title":"J Clin Oncol"},{"key":"2023010704070887700_bb0150","article-title":"The practice of nursing research: Appraisal, synthesis, and general evidence","author":"Burns","year":"2009"},{"key":"2023010704070887700_bb0155","article-title":"Defining sexual health: Report of a technical consultation on sexual health, 28\u201331 January 2002 [Internet]","author":"World Health Organization","year":"2006"},{"key":"2023010704070887700_bb0160","first-page":"81","article-title":"Female sexual dysfunction: Barriers to treatment","volume":"29","author":"Feldhaus-Dahir","year":"2009","journal-title":"Urol Nurs"},{"key":"2023010704070887700_bb0165","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1188\/07.CJON.671-675","article-title":"Sexuality assessment: 10 strategies for improvement","volume":"11","author":"Mick","year":"2007","journal-title":"Clin J Oncol Nurs"}],"container-title":["Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2050116115300246?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2050116115300246?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/smoa\/article-pdf\/2\/1\/8\/48407790\/smoa_2_1_8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/smoa\/article-pdf\/2\/1\/8\/48407790\/smoa_2_1_8.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T04:11:28Z","timestamp":1673064688000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/smoa\/article\/2\/1\/8\/6956196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/sm2.22","relation":{},"ISSN":["2050-1161"],"issn-type":[{"value":"2050-1161","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,4]]},"published":{"date-parts":[[2014,4,1]]}}}